Pilot Clinical Trial of Ketamine-assisted Psychotherapy for Methamphetamine Use Disorder and HIV Risk Reduction
The goal of this clinical trial is to learn whether it is possible to use intramuscular (IM) ketamine in combination with psychotherapy to treat moderate-to-severe methamphetamine use disorder (MeUD) in publicly insured patients with or at-risk for HIV disease. The main questions it aims to answer are: * Do publicly insured patients find ketamine-assisted psychotherapy feasible and acceptable as a potential treatment for MeUD? * Is IM ketamine safe and tolerable among patients with MeUD? Participants will: * Receive 3 monitored doses of IM ketamine * Have 3 preparation and 4 integration psychotherapy visits * Report their daily amounts of methamphetamine used prior to, during, and up to 3 months following the intervention
- Status
- active
- Phase
- Phase 2
- Institution
- Nicky Mehtani, MD, MPH
- Principal investigator
- Nicky Mehtani, MD MPH
- Start date
- 2025-03-04
- End date
- 2026-07-01
- Registry ID
- NCT06538285
Tracked by the DMT Code Clinical Trials Observatory, an open record of DMT-related clinical research.